Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19

We report on a patient with refractory Myasthenia gravis with acetylcholine receptor antibodies with two prior myasthenic crises suffering from COVID-19 with rapid evolving weakness and respiratory failure. Respiratory failure developed and prolonged mechanical ventilation was necessary. After plasm...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofstadt-van Oy, Ulrich, Stankovic, Slobodan, Kelbel, Corinna, Oswald, Daniel, Larrosa-Lombardi, Simon, Barchfeld, Thomas, Cleff, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Short Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857861/
https://www.ncbi.nlm.nih.gov/pubmed/33537898
http://dx.doi.org/10.1007/s00415-021-10428-6
_version_ 1783646528156467200
author Hofstadt-van Oy, Ulrich
Stankovic, Slobodan
Kelbel, Corinna
Oswald, Daniel
Larrosa-Lombardi, Simon
Barchfeld, Thomas
Cleff, Ulrich
author_facet Hofstadt-van Oy, Ulrich
Stankovic, Slobodan
Kelbel, Corinna
Oswald, Daniel
Larrosa-Lombardi, Simon
Barchfeld, Thomas
Cleff, Ulrich
author_sort Hofstadt-van Oy, Ulrich
collection PubMed
description We report on a patient with refractory Myasthenia gravis with acetylcholine receptor antibodies with two prior myasthenic crises suffering from COVID-19 with rapid evolving weakness and respiratory failure. Respiratory failure developed and prolonged mechanical ventilation was necessary. After plasmapheresis, residual, severe generalized and bulbar weakness persisted. Complement inhibition with eculizumab was, therefore, introduced and lead to rapid recovery. In refractory myasthenic crisis individualised therapies could be successful.
format Online
Article
Text
id pubmed-7857861
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-78578612021-02-04 Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19 Hofstadt-van Oy, Ulrich Stankovic, Slobodan Kelbel, Corinna Oswald, Daniel Larrosa-Lombardi, Simon Barchfeld, Thomas Cleff, Ulrich J Neurol Short Commentary We report on a patient with refractory Myasthenia gravis with acetylcholine receptor antibodies with two prior myasthenic crises suffering from COVID-19 with rapid evolving weakness and respiratory failure. Respiratory failure developed and prolonged mechanical ventilation was necessary. After plasmapheresis, residual, severe generalized and bulbar weakness persisted. Complement inhibition with eculizumab was, therefore, introduced and lead to rapid recovery. In refractory myasthenic crisis individualised therapies could be successful. Springer Berlin Heidelberg 2021-02-04 2021 /pmc/articles/PMC7857861/ /pubmed/33537898 http://dx.doi.org/10.1007/s00415-021-10428-6 Text en © Springer-Verlag GmbH, DE part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Short Commentary
Hofstadt-van Oy, Ulrich
Stankovic, Slobodan
Kelbel, Corinna
Oswald, Daniel
Larrosa-Lombardi, Simon
Barchfeld, Thomas
Cleff, Ulrich
Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19
title Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19
title_full Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19
title_fullStr Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19
title_full_unstemmed Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19
title_short Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19
title_sort complement inhibition initiated recovery of a severe myasthenic crisis with covid-19
topic Short Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857861/
https://www.ncbi.nlm.nih.gov/pubmed/33537898
http://dx.doi.org/10.1007/s00415-021-10428-6
work_keys_str_mv AT hofstadtvanoyulrich complementinhibitioninitiatedrecoveryofaseveremyastheniccrisiswithcovid19
AT stankovicslobodan complementinhibitioninitiatedrecoveryofaseveremyastheniccrisiswithcovid19
AT kelbelcorinna complementinhibitioninitiatedrecoveryofaseveremyastheniccrisiswithcovid19
AT oswalddaniel complementinhibitioninitiatedrecoveryofaseveremyastheniccrisiswithcovid19
AT larrosalombardisimon complementinhibitioninitiatedrecoveryofaseveremyastheniccrisiswithcovid19
AT barchfeldthomas complementinhibitioninitiatedrecoveryofaseveremyastheniccrisiswithcovid19
AT cleffulrich complementinhibitioninitiatedrecoveryofaseveremyastheniccrisiswithcovid19

Ejemplares similares